NRXP NRX Pharmaceuticals
- 2.1000
- +0.0400+1.94%
- 2.2000
- +0.1000+4.76%
NRX Pharmaceuticals News
Canopy Growth, Caredx, CytomX Therapeutics Among Healthcare Movers
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
GainersAkanda (NASDAQ:AKAN) shares moved upwards by 69.1% to $0.16 during Wednesday's pre-market session. The company's market cap stands at $1.8 million. NanoVibronix (NASDAQ:NAOV) shares moved upwar
12 Health Care Stocks Moving In Tuesday's After-Market Session
GainersPredictive Oncology (NASDAQ:POAI) shares rose 36.4% to $1.95 during Tuesday's after-market session. The company's market cap stands at $7.9 million. Brainstorm Cell (NASDAQ:BCLI) shares moved u
BKKT, CETX and SWVL Among Mid-day Movers
Cyclacel CYCC Private Placement; NRx Pharmaceuticals NRXP Phase 2b/3 Failure
Why H&E Equipment Services Shares Are Trading Lower By Around 18%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Shares of H&E Equipment Services, Inc. (NASDAQ:HEES) fell sharply during Tuesday's session following mixed first-quarter results.H&E Equipment posted GAAP earnings of 71 cents per share, versus market
Why Is NRx Pharmaceuticals Stock Falling After Data From Suicidal Bipolar Depression Study
NRx Pharmaceuticals Inc (NASDAQ:NRXP) shares are down 23.1% at $2.73 at last check Tuesday.The stock plummet occurred on the heels of the company's latest study: the Phase 2b/3 trial of NRX-101 vs. Lu
Annovis Bio, Cyclacel Pharmaceuticals, Biodexa Pharmaceuticals Among Healthcare Movers
NRx Pharmaceuticals Shares Are Trading Lower After the Company Announced Findings From Its Phase 2b/3 Trial of NRX-101 Vs. Lurasidone.
NRx Pharmaceuticals Shares Are Trading Lower After the Company Announced Findings From Its Phase 2b/3 Trial of NRX-101 Vs. Lurasidone.
NRx Pharmaceuticals (Nasdaq:NRXP) Announces Promising Findings in Phase 2b/3 Clinical Trial of NRX-101 Vs. Lurasidone for Treatment of Suicidal Bipolar Depression
NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical stage pharmaceutical company today that its Breakthrough...
NRx Pharmaceuticals, Inc. (NRXP) Advances While Market Declines: Some Information for Investors
Benitec PIPE & Phase 1b/2a Data; NRX Pharmaceuticals NRXP Offering
NRX Pharmaceuticals Shares Are Trading Lower After the Company Announced the Pricing of a $2 Million Underwritten Public Offering.
NRX Pharmaceuticals Shares Are Trading Lower After the Company Announced the Pricing of a $2 Million Underwritten Public Offering.
CGC, GENE and HOLO Among Mid-day Movers
Crude Oil Edges Lower; Bio-Path Holdings Shares Spike Higher
U.S. stocks traded higher midway through trading, with the S&P 500 gaining around 0.5% on Thursday.The Dow traded up 0.64% to 37,996.39 while the NASDAQ rose 0.41% to 15,747.36. The S&P 500 also rose,
Why Las Vegas Sands Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Shares of Las Vegas Sands Corp. (NYSE:LVS) fell sharply during Thursday's session despite better-than-expected first-quarter results.The company reported quarterly adjusted earnings of 75 cents per sh
Dow Surges Over 100 Points; D.R. Horton Posts Upbeat Earnings
U.S. stocks traded mixed this morning, with the Dow Jones index gaining more than 100 points on Thursday. Following the market opening Thursday, the Dow traded up 0.34% to 37,880.89 while the NASDAQ f
NRx Pharmaceuticals Shares Drop 27% After Public Offering Prices
By Chris Wack NRx Pharmaceuticals shares were down 27% to $3.05 after the company priced its underwritten public offering of shares at $3.30 a share. The stock is now down 51% in the past 12 months.
NRx Pharmaceuticals (NASDAQ:NRXP) Receives Notice From Nasdaq That the Company Has Demonstrated Compliance With the Bid Price Requirement
NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) ("NRx Pharmaceuticals", "NRx", the "Company"), a clinical-stage biopharmaceutical company, today announced...
NRx Pharmaceuticals, Inc. Announces Pricing of $2.0 Million Underwritten Public Offering of Common Stock
NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), ("NRx Pharmaceuticals" or the "Company"), a clinical-stage biopharmaceutical company, today announced the...
Analysis
Price Target
No Data
